Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatient Japanese participants diagnosed with MDD
Diagnosis of moderate or greater severity of MDD
Agree to abstain from sexual activity or to use a reliable method of birth control
Judged to be reliable (agree to keep appointments for clinic visits and to undergo all tests and examinations required by the protocol)
You may not be if
Have previously been exposed to fluoxetine (LY110140) for any indication in the past
Significant suicidal risk
Have a current or previous diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive disorder, or post-traumatic stress disorder
Have a history of substance abuse or dependence within the past 6 months, excluding caffeine and nicotine
Have initiated, stopped, or changed the type or intensity of psychotherapy within 6 weeks
Have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS) within 1 year
Have had treatment with a Monoamine oxidase inhibitor (MAOI) within 14 days
Need to use thioridazine or pimozide during the study
Have previously enrolled, completed, or withdrawn from this study
Have a positive urine drug screen for drugs with abuse potential
Female participants who are either pregnant, nursing, or have recently given birth, or male participants who are planning for their partners to be or become pregnant
Have a history of seizure disorder
Have frequent or severe allergic reactions to multiple medications
Have a serious or unstable medical illness or condition, or psychological condition
Participants deemed ineligible by the investigator or sub-investigator for other reasons
Clareo Health | A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
